GEVORKYAN w H1 2026: przychody +18%, zysk netto +34%

GEVORKYAN reported H1 2026 revenue of €49.8m, up 18.18% year over year, while net profit rose 34.50% to €3.97m. EBITDA increased 9.19% to €15.04m, producing a 30.19% EBITDA margin, and EBIT climbed 29.06% to €6.68m. Its Italian acquisition has begun supplying Rheinmetall, while EN 9100 certification opens aerospace, space and defense-project opportunities, including aircraft and unmanned systems.

Analysis

The key signal is not the reported growth rate but the mix shift: aerospace/defense qualification can lengthen customer programs and raise switching costs versus GEVORKYAN's more cyclical automotive and industrial powder-metallurgy exposure. The current margin trajectory suggests the acquired Italian capacity is not yet fully dilutive, but EBITDA growing below revenue indicates integration, ramp-up, or product-mix costs are already absorbing part of incremental gross profit. The next 1-3 months hinge on whether the interim filing discloses order backlog, defense/aerospace revenue concentration, working-capital consumption, and net-debt/EBITDA; without these, the earnings release is insufficient to underwrite a durable re-rating.

Rheinmetall's direct earnings sensitivity is immaterial: GEVORKYAN is better viewed as a small-cap bottleneck supplier levered to European defense localization rather than as a read-through to RHM's demand. EN 9100/OASIS access expands the addressable bid universe, but certification alone does not create revenue; aerospace conversion cycles commonly run 12-36 months after qualification. The more valuable second-order outcome would be pricing power and utilization gains if European OEMs dual-source away from Asian powder-metal suppliers amid procurement-security requirements.

Consensus may overvalue the defense narrative before contracts become visible. A lower EBITDA-growth rate than sales, potential customer concentration in the Italian operation, and elevated receivables/inventory from program launches could cap free-cash-flow conversion even if reported earnings continue to rise. Falsify the constructive view if H2 guidance implies sub-30% EBITDA margin, net leverage rises materially, or disclosed defense/aerospace backlog fails to support at least mid-teens organic growth into 2027.

Key Decisions for Investors

• Maintain GEV as a watch-list long rather than initiating on the release; enter only after the full interim report confirms positive operating cash flow, stable or lower net-debt/EBITDA, and disclosed backlog supporting H2 growth. Initial sizing should reflect small-cap liquidity risk; thesis horizon is 6-18 months.
• For an existing GEV position, add selectively on post-report weakness only if EBITDA margin holds near 30% and Italian integration does not require incremental capital or restructuring charges. Exit/reduce on a sustained margin break below 28% or a material increase in customer concentration.
• Do not use RHM as a directional sympathy trade: the supplier relationship is too small to alter Rheinmetall estimates. Use RHM exposure independently for European defense-budget catalysts, while monitoring it as validation only if procurement disclosures indicate broader platform-program ramping.
• Set an alert for first named aerospace/defense program awards, contract duration, and backlog conversion milestones over the next 3-12 months. Those disclosures—not certification—would justify revisiting a higher valuation multiple for GEV.